Physician profile
Charles E Wessel
NPI 1275525909
$621.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $145 · 2021: $202 · 2022: $96.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.01 | 2019-2021 | |
| Allergan, INC. | $117.61 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.84 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $35.76 | 2021 | |
| Phadia US INC. | $34.00 | 2020-2021 | |
| Pfizer INC. | $29.28 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $24.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2022 | |
| Abbvie INC. | $22.96 | 2021 | |
| Glaxosmithkline, LLC. | $15.47 | 2022 | |
| Lilly USA, LLC | $11.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wessel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.